Summit Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For thetransition period from _________ to _________Commission File Number: 001-36866_______________________________Summit Therapeutics Inc.(Exact name of registrant as specified in its charter)_____________________ 37-1979717 (State or other jurisdiction ofincorporation or organization) (I.R.S. Employer IdentificationNo.) (Address of principal executive offices) 601 Brickell Key Drive, Suite 1000, Miami, FL 305-203-2034 (Registrant’s telephone number, including area code)Not Applicable (Former name or former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of April24, 2026, there were 776,162,645 shares of common stock, par value $0.01 per share, outstanding. TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking StatementsPART IFINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management's Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART IIOTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities LitigationReform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”), regarding the future financial performance, business prospects and growth of Summit TherapeuticsInc., that involve substantial risks and uncertainties. All statements contained in this Quarterly Report on Form 10-Q, other thanstatements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues,projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,”“estimate,”“expect,”“intend,”“may,”“plan,”“predict,”“project,”“target,”“potential,”“will,”“would,”“could,”“should,”“continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statementscontain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things,statements about: •the ability to develop a successful product candidate under the License Agreement (as defined in Part I, Item 1 FinancialStatements, Note 1 Organization);•our ability to raise sufficient additional funds to make payments under the License Agreement, and fund ongoing operationsand capital needs;•the timing of and the ability to effectively execute clinical development of ivonescimab;•the timing, costs, conduct and outcomes of clinical trials for any product candidates, including ivonescimab;•our plans with respect to possible future collaborations and partnering arrangements;•the potential benefits of possible future acquisitions or investments in other bu